Liquidia Corporation to Present at Upcoming Investor Conferences in September 2024
Accessing the Webcasts
Investors and interested parties can access the webcasts of these presentations through Liquidia's website at https://liquidia.com/investors/events-and-presentations. Recorded versions of the presentations will be available on the company's website for at least 30 days following each event, providing an opportunity for those unable to attend live to review the information presented.
A Focus on Rare Cardiopulmonary Diseases
Liquidia Corporation is a leading biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare cardiopulmonary diseases. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. This technology has been instrumental in the creation of Liquidia's lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Expanding its Portfolio
Beyond YUTREPIA™, Liquidia is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer. The company also currently markets generic Treprostinil Injection for the treatment of PAH.
These upcoming presentations at the Wells Fargo Healthcare Conference and the Cantor Global Healthcare Conference offer Liquidia a valuable platform to showcase its progress in developing innovative therapies for patients with rare cardiopulmonary diseases and its commitment to delivering effective treatments to those who need them most. These events will also provide an opportunity for investors to gain deeper insights into the company's vision and strategic direction.
Looking Forward: Liquidia's Future in Rare Cardiopulmonary Disease
Liquidia's focus on rare cardiopulmonary diseases, its dedication to innovative therapies, and its commitment to clinical excellence position the company for continued success. As the company navigates the complex landscape of rare disease drug development, its participation in these upcoming investor conferences is a testament to its ambition and its dedication to making a positive impact on the lives of patients. With a focus on delivering effective treatments and a commitment to research and development, Liquidia is poised to become a leading force in the field of rare cardiopulmonary disease therapy.
